Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

May 26, 2020

US FDA approves Takeda’s ALUNBRIG for rare and serious form of lung cancer

Takeda Pharmaceutical Company announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

US FDA approves Takeda’s ALUNBRIG for rare and serious form of lung cancer